 SAN MATEO, Calif.--BUSINESS WIRE--Sierra Oncology, Inc. SRRA, a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual 